{
  "id": "UCLA_Integrated_Staging_System_UISS_for_Renal_Cell_Carcinoma_RCC_guideline.v1",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2020-10-16",
      "name": "Maryam Razavi",
      "organisation": "CambioCDS",
      "email": "maryam.razavi@cambio.se"
    },
    "lifecycle_state": "Author draft",
    "details": {
      "en": {
        "id": "en",
        "purpose": "To provide 5-year disease-free prognosis for localized and metastatic RCC.",
        "keywords": [
          "Renal Cell Carcinoma",
          "T stage",
          "Fuhrman nuclear grade",
          "ECOG Performance Status",
          "Metastatic",
          "Localized"
        ],
        "use": "Use for patients with RCC, localized or metastatic, particularly those being considered for clinical trial enrollment.\nVariables: \nLocalized: Any T; N0; M0\nMetastatic: T>0; N>1; M>1\nFor accurate staging, see the TNM Staging for RCC. \nThis score placed patients with local or metastatic renal cell carcinoma (mRCC) into mortality risk groups: low, intermediate/moderate, and high.\nFORMULA:\nAddition of the selected points. \n\nInterpretation: \nDisease Type: Local Disease = Low Risk Group= 91.1% Five-year disease-specific survival\nDisease Type: Local Disease = Intermediate Risk Group= 80.4% Five-year disease-specific survival\nDisease Type: Local Disease = High Risk Group= 54.7% Five-year disease-specific survival\nDisease Type: Metastatic Disease = Low Risk Group= 32% Five-year disease-specific survival\nDisease Type: Metastatic Disease = Intermediate Risk Group= 19.5% Five-year disease-specific survival\nDisease Type: Metastatic Disease = High Risk Group= 0% Five-year disease-specific survival\n\n\n\n",
        "copyright": "@CambioCDS"
      }
    },
    "other_details": {
      "references": "1. Zisman A,Pantuck AJ,Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002; 20: 4559–4566.\n2. Patard J, et al. Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. JCO Aug 15, 2004:3316-3322\n3. Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012; 23(suppl 7):vii65–vii71.\n"
    }
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-OBSERVATION.ucla_integrated_staging_system_uiss_for_renal_cell_carcinoma_rcc.v0",
        "template_id": "openEHR-EHR-OBSERVATION.ucla_integrated_staging_system_uiss_for_renal_cell_carcinoma_rcc.v0",
        "type": "INPUT",
        "elements": {
          "gt0003": {
            "id": "gt0003",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          },
          "gt0004": {
            "id": "gt0004",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0008]"
          },
          "gt0005": {
            "id": "gt0005",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0013]"
          },
          "gt0007": {
            "id": "gt0007",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0034]"
          },
          "gt0008": {
            "id": "gt0008",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0037]"
          },
          "gt0020": {
            "id": "gt0020",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0018]"
          }
        }
      },
      "gt0009": {
        "id": "gt0009",
        "model_id": "openEHR-EHR-OBSERVATION.ucla_integrated_staging_system_uiss_for_renal_cell_carcinoma_rcc.v0",
        "template_id": "openEHR-EHR-OBSERVATION.ucla_integrated_staging_system_uiss_for_renal_cell_carcinoma_rcc.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0010": {
            "id": "gt0010",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0021]"
          },
          "gt0011": {
            "id": "gt0011",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0025]"
          }
        }
      }
    },
    "rules": {
      "gt0014": {
        "id": "gt0014",
        "priority": 6,
        "when": [
          "$gt0003|Type of disease present|==local::at0006|Localized|",
          "$gt0004|Localized disease - T stage|==local::at0009|T1|",
          "$gt0005|Fuhrman nuclear grade|.value<=2",
          "$gt0020|ECOG Performance Status|.value==0"
        ],
        "then": [
          "$gt0010|Risk|=local::at0022|Low|",
          "$gt0011|Five-year disease-specific survival|=local::at0026|91.1%|"
        ]
      },
      "gt0012": {
        "id": "gt0012",
        "priority": 5,
        "when": [
          "$gt0003|Type of disease present|==local::at0006|Localized|",
          "((($gt0004|Localized disease - T stage|==local::at0009|T1|)&&($gt0005|Fuhrman nuclear grade|.value<=2))&&($gt0020|ECOG Performance Status|.value>=1))||(((($gt0004|Localized disease - T stage|==local::at0009|T1|)&&($gt0005|Fuhrman nuclear grade|.value>=3))&&($gt0020|ECOG Performance Status|!=null))||(((($gt0004|Localized disease - T stage|==local::at0010|T2|)&&($gt0005|Fuhrman nuclear grade|!=null))&&($gt0020|ECOG Performance Status|!=null))||(((($gt0004|Localized disease - T stage|==local::at0011|T3|)&&($gt0005|Fuhrman nuclear grade|.value==1))&&($gt0020|ECOG Performance Status|!=null))||((($gt0004|Localized disease - T stage|==local::at0011|T3|)&&($gt0005|Fuhrman nuclear grade|.value>1))&&($gt0020|ECOG Performance Status|.value==0)))))"
        ],
        "then": [
          "$gt0010|Risk|=local::at0023|Intermediate|",
          "$gt0011|Five-year disease-specific survival|=local::at0027|80.4%|"
        ]
      },
      "gt0015": {
        "id": "gt0015",
        "priority": 4,
        "when": [
          "$gt0003|Type of disease present|==local::at0006|Localized|",
          "((($gt0004|Localized disease - T stage|==local::at0011|T3|)&&($gt0005|Fuhrman nuclear grade|.value>1))&&($gt0020|ECOG Performance Status|.value>=1))||($gt0004|Localized disease - T stage|==local::at0012|T4|)"
        ],
        "then": [
          "$gt0010|Risk|=local::at0024|High|",
          "$gt0011|Five-year disease-specific survival|=local::at0028|54.7%|"
        ]
      },
      "gt0016": {
        "id": "gt0016",
        "priority": 3,
        "when": [
          "$gt0003|Type of disease present|==local::at0005|Metastatic|",
          "(((($gt0007|Metastatic disease - N stage|==local::at0035|N1|)&&($gt0008|Metastatic disease - M stage|==local::at0038|M0|))&&($gt0005|Fuhrman nuclear grade|!=null))&&($gt0020|ECOG Performance Status|!=null))||(((($gt0007|Metastatic disease - N stage|==local::at0036|N2|)&&($gt0008|Metastatic disease - M stage|!=null))&&($gt0005|Fuhrman nuclear grade|.value<=2))&&($gt0020|ECOG Performance Status|==0|local::at0045|Asymptomatic|))"
        ],
        "then": [
          "$gt0010|Risk|=local::at0022|Low|",
          "$gt0011|Five-year disease-specific survival|=local::at0029|32%|"
        ]
      },
      "gt0017": {
        "id": "gt0017",
        "priority": 2,
        "when": [
          "$gt0003|Type of disease present|==local::at0005|Metastatic|",
          "$gt0007|Metastatic disease - N stage|==local::at0036|N2|",
          "$gt0008|Metastatic disease - M stage|!=null",
          "(($gt0005|Fuhrman nuclear grade|.value<=2)&&($gt0020|ECOG Performance Status|.value>=1))||((($gt0005|Fuhrman nuclear grade|.value==3)&&($gt0020|ECOG Performance Status|!=null))||(($gt0005|Fuhrman nuclear grade|.value==4)&&($gt0020|ECOG Performance Status|.value==0)))"
        ],
        "then": [
          "$gt0010|Risk|=local::at0023|Intermediate|",
          "$gt0011|Five-year disease-specific survival|=local::at0030|19.5%|"
        ]
      },
      "gt0018": {
        "id": "gt0018",
        "priority": 1,
        "when": [
          "$gt0003|Type of disease present|==local::at0005|Metastatic|",
          "$gt0007|Metastatic disease - N stage|==local::at0036|N2|",
          "$gt0008|Metastatic disease - M stage|!=null",
          "$gt0005|Fuhrman nuclear grade|.value==4",
          "$gt0020|ECOG Performance Status|.value>=1"
        ],
        "then": [
          "$gt0010|Risk|=local::at0024|High|",
          "$gt0011|Five-year disease-specific survival|=local::at0031|0%|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC)",
            "description": "UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC) provides 5-year disease-free prognosis for localized and metastatic RCC."
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Type of disease present",
            "description": "*"
          },
          "gt0004": {
            "id": "gt0004",
            "text": "Localized disease - T stage",
            "description": "*"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Fuhrman nuclear grade",
            "description": "Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma provides prognostic grading system for tumor cells based on physical cellular appearance."
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Metastatic disease - N stage",
            "description": "*"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Metastatic disease - M stage",
            "description": "*"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Risk",
            "description": "*"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Five-year disease-specific survival",
            "description": "*"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Set Localized to Intermediate risk and 80.4% survival"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Set Localized disease to Low risk and 91.1% survival"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Set Localized to High  risk and 54.7% survival"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Set Metastatic disease to Low risk and 32% survival"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "Set Metastatic disease to Intermediate risk and 19.5% survival"
          },
          "gt0018": {
            "id": "gt0018",
            "text": "Set Metastatic disease to High risk and 0%  survival"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "ECOG Performance Status",
            "description": "*"
          }
        }
      }
    }
  }
}